about
Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohortHigh levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort.Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis.The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies.Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis.Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical RemissionMicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritisThe relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis - a cohort study.Treatment-resistant inflammatory myopathy.Clinical trials roundup in idiopathic inflammatory myopathies.Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations.MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies.Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience.Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.Inflammatory myopathy associated with statins: report of three cases.Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis.Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial.A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.Delays in assessment of patients with rheumatoid arthritis: variations across Europe.CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study.Dr. Vencovsky, et al replyOP0289 A Prospective, Randomized, Open-Label, Assessor-Blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids versus Glucocorticoids Alone in Patients with Polymyositis and Dermatomyositis (PrometheuSAT0349 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study: Table 1AB0009 Association of MHC Haplotypes with Idiopathic Inflammatory Myopathy in Cohort of Czech PatientsFRI0520 Association Study of the BAFF Genetic Variations in Two Independent Cohorts with Idiopathic Inflammatory MyopathiesTHU0528 Decrease in Circulating Visfatin Levels is Associated with Disease Activity Improvement in Early Rheumatoid ArthritisA1.48 Enhanced expression of CD11c on non-classical CD16+peripheral blood monocytes in early rheumatoid arthritisAnti-Ro52 epitope mapping in inflammatory myopathiesSerum levels of interferon do not correlate with disease activity in patients with dermatomyositis/polymyositisThe metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathiesFactors influencing health status and disability of patients with ankylosing spondylitis in the Czech RepublicSerum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study
P50
Q30839061-D42A41C6-D956-4BFA-AFB3-FA64513BA384Q30876263-567A10F0-026E-4664-B805-FA4A50370227Q34237586-09E96B09-FE11-4C4B-A85E-320EF90918F7Q34560305-8A7D94E6-D287-4E52-94BB-D54EF51EFE96Q35617658-CDC3BA17-3860-4974-97D6-94A2C4C5FD73Q35882730-7345CBD0-3E0C-4963-978F-B03552D72520Q36067062-F31E42E7-BCAE-4BB7-914F-802986012EEAQ36188496-D97C6240-EAEB-4317-93B0-60971843FE79Q36960767-052FF451-6C4F-47CB-BFD6-19FB5721DA79Q37586470-176F3F7E-356F-4B6F-9DBC-5B8B964F3DD8Q37763782-B3946BAA-2556-46AA-BF35-EB4BAF7FE3CAQ37934396-3BAB1333-9F35-40BA-A141-192941A74F22Q38208567-5B3EF516-C486-40E1-B0FA-E929C136B3A0Q38644438-B5C04307-6BA1-4D3D-A294-CF9482E4C65AQ40799107-E1AEF19F-5A45-4B9D-8BE1-AE0CA60A1D3BQ41497288-FA1BB0DD-C2A3-4E9A-98B0-2783873574A6Q42706490-4859AF53-FBD9-4487-B0FE-24AF83B14D44Q43204037-248118D4-87A3-4FCE-8041-345D6F3D0AECQ46483118-BDCFDA4D-0407-4326-805E-32AD44D2F2F5Q47674978-E02A6E75-71A5-417F-B275-0AD0E854C6D4Q51060022-B432C8F7-DB5E-43ED-93D0-2DAC871598C4Q52893591-7E54C144-3819-4EB6-835F-F357E5A1C0AFQ54324459-CF884A90-4AD2-4286-B451-58C74376E33EQ57752304-1DEF6F88-6645-4677-ABE4-A05AEAFEFC78Q57752319-0ADE12CA-4185-4009-8E77-D90644F5E324Q57752324-CA03E3BB-2068-4A81-908F-F75459999C36Q57752332-D2209E30-0DAE-49B8-A6D7-5BB47A1A19E1Q57752335-DBA84D95-CBAC-4EF8-9DD6-F03E906388F8Q57752350-6AA2E83C-D014-430C-B1B8-8A6075F24EAEQ57752360-1B7329F0-4D5B-4E27-8ED1-3C7C0A5E7E99Q57752454-891D1957-6534-4DA6-AE9E-2964821FDB87Q57752562-B39BDAAE-859C-4E54-BE32-9AB2D91483ADQ57752577-374E2302-FC88-470B-90CE-971B4E6B5145Q80625220-1CAB26AF-A496-4F7F-B1FC-06F15377D4D7Q91532373-8F3843EB-04EF-4A60-B85A-1B2AE8E0DD92
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Herman Mann
@ast
Herman Mann
@en
Herman Mann
@es
Herman Mann
@nl
type
label
Herman Mann
@ast
Herman Mann
@en
Herman Mann
@es
Herman Mann
@nl
prefLabel
Herman Mann
@ast
Herman Mann
@en
Herman Mann
@es
Herman Mann
@nl
P106
P1153
25959639300
P31
P496
0000-0002-4243-235X